



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Bethesda, Maryland 20892

May 25, 2016

J. Donald Easton, M.D.
Clinical Professor
UCSF Department of Neurology
Sandler Neurosciences Center
675 Nelson Rising Lane
San Francisco, CA 94158-0663

Dear Dr. Easton:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met by in Newark, NJ on May 2, 2016 to review all interim data from the trial. The DSMB said the study investigators are doing an excellent job in managing the trial and there are no safety concerns. The DSMB thus recommended the trial proceed as planned.

The next meeting of the DSMB will be scheduled for November 2016.

Sincerely,

A handwritten signature in blue ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.
Clinical Research Project Manager
Office of Clinical Research
National Institute of Neurological Disorders and Stroke
National Institutes of Health
6001 Executive Boulevard, Suite 2202
Bethesda, MD 20892-9525